Solar Food’s protein from carbon dioxide gets authorisation
Finnish Solar Foods Ltd has got the first ever novel food authorisation for its microbially-produced protein powder Solein.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2171 entries already.
Entries by Thomas Gabrielczyk
The pharma lab in times of cell & gene therapies
After two years online, PharmaLab 2022 returns on site for its 10th edition. Over three days, the congress will offer the opportunity to share the latest experiences with colleagues and to exchange ideas in person.
Bone Therapeutics merges with Medsenic and changes name
Bone Therapeutics has merged with French inflammatory/autoimmune company Medsenic in a €40m deal and changed its name into BioSenic.
Resolve Biosciences secures US$71m in funding
Molecular cartography company Resolve Biosciences has raised $71m in series B funding co-led by Patient Square Capital, EDBI, Alafi Capital and NRW.BANK as well as other existing investors.
Enhanc3D Genomics raises £10m in Series A financing
Cambridge-based Enhanc3D Genomics Ltd has raised £10m in Series A financing led by BGF and Parkwalk Advisors.
Univercells SA raises €44m in first close of its Series D
Belgian CDMO Univercells SA has raised €44m through the first close of its Series D financing round led by Belgian and international investors. I
PULSE: At the heart of Switzerland’s health valley
Most people know Switzerland for its watches, mountains, and chocolate. But biopharma professionals know that this country in the heart of Europe offers much more: the ideal setting for innovation and production in the fields of pharma and biotech.
Adrenomed set to start pivotal trial in sepsis
German Adrenomed AG has got a recommendation from the EMA to push its Adrenomedullin-binding antibody Adrecizumab into a pivotal Phase III study.
A spotlight on tomorrow’s CRO
The CRO industry is predicted to grow considerably over the next five years. Trials are becoming more complex, and technology is becoming increasingly interwoven with processes. The CRO of tomorrow must be tech smart, agile, and environmentally conscious to remain relevant. In this changing landscape, how does a CRO cut through the noise in 2022-30?
Mablink raises $31m in Series A financing
Mablink Bioscience has baged €31m in a Series A round led by Sofinnova Partners and Mérieux Equity Partners to speed up its pipeline of ADCs.